Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - BIO-PATH HOLDINGS INC | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): November 2,
2009
BIO-PATH
HOLDINGS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Utah
(State or
Other Jurisdiction of Incorporation)
|
000-53404
|
87-0652870
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
3293
Harrison Blvd., Ste. 230, Ogden, UT
|
84403
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
801-399-5500
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other
Events.
On November 2, 2009, Bio-Path Holdings,
Inc. (the “Company”) issued a press release announcing that the suppliers for
the Company’s lead drug candidate have successfully manufactured the clinical
drug batch and all release testing required for this drug has been
completed. As a result, in October the Company submitted the
necessary drug batch manufacturing and testing data to the FDA. If
FDA reviewers have no additional request for information, the Company
anticipates that, within thirty (30) days after such determination, the
Investigational New Drug (IND) application for the Company’s lead drug candidate
will be released. In such event, the Company would then be able to
commence its Phase I clinical trial.
Item 9.01 Financial
Statements and Exhibits.
|
B.
|
Exhibits
|
(attached)
|
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
|
Dated: November
3, 2009
|
BIO-PATH
HOLDINGS, INC.
|
|
By: /s/
Peter Nielsen
|
|
|
Chief
Executive Officer
|
2